JNJ-4916
/ J&J
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
July 24, 2025
Phase I study of intratumoral administration of JNJ-87704916, an oncolytic virus, as monotherapy and in combination with cetrelimab in advanced solid tumors
(ESMO 2025)
- "Two pts with IO refractory advanced melanoma experienced Partial Responses at 6 weeks that are still ongoing at 20 and 25 weeks, including evidence of response in uninjected lesions and deepening of response with time. Conclusions IT injection of JNJ-4916 demonstrated acceptable safety when combined with CET, with evidence of systemic disease control in 2 pts with anti-PD1 refractory metastatic melanoma."
Combination therapy • IO biomarker • Metastases • Monotherapy • Oncolytic virus • P1 data • Melanoma • Oncology • Solid Tumor • CD40 • IFNG • IL12A
September 13, 2025
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=96 | Recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | Trial completion date: Nov 2033 ➔ Aug 2032
Monotherapy • Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor
October 21, 2024
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=96 | Recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | N=66 ➔ 96
Enrollment change • Metastases • Monotherapy • Oncolytic virus • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
March 28, 2024
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=66 | Recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Monotherapy • Oncolytic virus • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
March 15, 2024
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=66 | Not yet recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc.
Metastases • Monotherapy • New P1 trial • Oncolytic virus • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1